Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of the Safety and Preliminary Efficacy of Recombinant Human Arginase 1 (rhArg1) in Patients With Relapsed or Refractory Leukemia or Lymphoma

NCT01551628 is registered in ClinicalTrials.gov with Bio-Cancer Treatment International Limited as lead sponsor.

NCT NCT01551628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01551628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of the Safety and Preliminary Efficacy of Recombinant Human Arginase 1 (rhArg1) in Patients With Relapsed or Refractory Leukemia or Lymphoma
Lead sponsor
Bio-Cancer Treatment International Limited
Phase
Phase 1
Overall status
Terminated
Start date
April 30, 2012
Completion date
May 31, 2013
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, lymphoma